2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Hall C
This session surveys the latest early-phase clinical data shaping the treatment landscape for chronic myelomonocytic leukemia (CMML), higher-risk myelodysplastic syndromes (MDS), and MDS/MPN overlap disorders. Presentations span first-in-human results for a novel CCR2-targeting cytotoxicity chimera, combination regimens pairing hypomethylating agents with venetoclax and other cytotoxic or immune-targeting partners (anti-CD47, anti-IL1RAP), and an all-oral treatment approach for MDS/MPN overlap syndromes. A pediatric-focused study extends the discussion to secondary myeloid neoplasms. Together, these studies reflect the field's ongoing shift toward targeted and combination-based strategies aimed at improving outcomes across this heterogeneous group of hard-to-treat myeloid malignancies.
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Immunotherapy, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

534 Clinical efficacy of cladribine, low dose cytarabine and venetoclax alternating with azacitidine and venetoclax, in advanced chronic myelomonocytic leukemia: Results of a phase II study

Guillermo Montalban-Bravo, MD, Sanam Loghavi, MD2, Naval Daver, MD3, Nicholas Short, MD4, Yesid Alvarado Valero, MD5, Kelly Sharon Chien, MD6, Gautam Borthakur, MD7, Ghayas C. Issa, MD8, Elias Jabbour, MD9, Courtney DiNardo, MD, MSCE10, Mahesh Swaminathan, MD11, Abhishek Maiti, MBBS12, Danielle Hammond, MD13, Jo Ishizawa, MD, PhD14, Maro Ohanian, DO15, Lucia Masarova, MD16, Steven Kornblau, MD17, Prithviraj Bose, MD18, Alex Bataller, MD, PhD19, Fadi G. Haddad, MD20, Alexandre Bazinet, MD21, Chenxuan Zang22, Ziyi N/A Li23, Xuelin Huang, PhD24, Beenu Thakral, MD25, Sa Wang, MD26, Wei Wang, MD, PhD27, Carlos Bueso-Ramos, M.D., Ph.D.28, Pezhman Hosseinpoor29, Hsinyi Lu30, Hui Yang, MD, PhD31, Yue Wei, PhD32, Heather Schneider, BSN, RN33, Stephany Hendrickson34, Cara Haymaker35, Tapan Kadia I, MD36, Guillermo Garcia-Manero, MD37
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
32 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
33 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
34 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
35 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
36 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
37 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Therapeutic options for patients (pts) with chronic myelomonocytic leukemia (CMML) remain limited. This results in poor outcomes and risk of transformation to acute myeloid leukemia (AML). Transformation is driven by expansion of hypomethylating agent/venetoclax (VEN)-resistant bone marrow (BM) CD34+ myeloid progenitors and immature monocytic precursors, which depend on NF-kB-mediated survival mechanisms such as MCL1 and on purine/pyrimidine metabolism. Cladribine (CDA), a purine nucleoside analogue, has shown clinical activity in AML when combined with low-dose cytarabine (LDAC) and VEN. Here, we report the results of a study evaluating this combination in pts with high-risk CMML.

Methods: We designed a phase II clinical trial (NCT05365035) for newly diagnosed (ND) or relapsed/refractory (R/R) CMML and other myeloid neoplasms. Results for CMML pts are reported here. Induction consisted of CDA 5mg/m2 daily IV for 3-4 days, LDAC 20mg s.c bid for 5-7 days and VEN 400mg daily for 7-10 days followed by azacitidine 75mg/m2 daily days 1-7 with venetoclax 400mg daily days 1-7 or CDA 5mg/m2 days 1-3, LDAC 20mg s.c bid days 1-5 and VEN 400mg days 1-7 alternating every 2 cycles. Primary end points included safety and efficacy. Longitudinal next-generation sequencing was performed at baseline and response assessment (n=20). CD34+ myeloid progenitors, monocyte and immature monocyte (ImMono) populations were sequentially quantified by flow cytometry (n=23). Longitudinal single-cell RNA-sequencing (scRNA-seq) of BM mononuclear cells (MNCs) was performed in select patients (n=4).

 Results: As of 06/2026, 38 pts have been treated (23 ND and 15 R/R), including 19 (50%) with myeloproliferative (MP) CMML, 23 (63%) with CMML-2 and 2 (5%) with non-hepatosplenic extramedullary disease. Median age was 73 years (range 52-80). CPSS-Mol risk was Int-1 in 7 pts (18%), Int-2 in 13 (37%), and High in 16 (45%).  Median number of prior therapies in R/R pts was 1 (range 1-4): 2 (13%) had prior VEN and 1 (7%) prior allogeneic stem-cell transplant (SCT).
Pts received a median of 2 cycles (1-13), with achievement of best response after a median of 1 cycle (R/R: range 1-2; ND: 1-5). By 2015 MDS/MPN response criteria, the ORR was 53% in R/R pts (n=8; optimal marrow response [optMR]: 7 [47%]; partial marrow response: 1 [7%]) and 74% in ND pts (n=17; CR: 6 [26%]; optMR: 10 [44%]; clinical benefit (CB): 1 [4%]; complete cytogenetic response: 2/5 [40%]).  White blood cell reduction to <10x109/L was observed in 18/20 (90%) pts with WBC >10x109/L at enrollment. Absolute monocyte reduction to <1x109/L was achieved in 60% of pts.
The 4- and 8-week mortality were 0%. Most common grade =/> 3 treatment-emergent adverse events (TEAEs) were thrombocytopenia (n=20, 53%), neutropenia (n=12, 32%) and febrile neutropenia (n=8, 21. Most cytopenias were transient: neutrophil recovery to >1×10?/L occurred in 86% of R/R and 81% of ND pts (median 29 days), and platelet recovery to >100×10?/L in 57% and 88%, respectively (median 23 days). Dose reductions were required in 8 (21%) of pts. No patient discontinued therapy due to TEAEs. At time of data cut-off 2 (5%) pts remain on study, 16 (42%) proceeded to SCT and 4 (11%) had AML progression.
With a median follow-up of 14 months, median overall survival was not reached for ND pts and is 16 months for R/R pts. Median leukemia-free survival was not reached for ND and is 16 months for R/R pts. No survival differences were observed among pts based on presence of RAS pathway (RASp) mutations or MP-CMML.
Response to therapy was associated with variant allele frequency reductions of baseline somatic mutations, predominantly of RASp and RUNX1, and reduction of CD34+ progenitors and ImMonos, but not of mature monocytes. Accordingly, scRNA-seq revealed reduced promonocyte frequencies and downregulation of genes involved in NF-kB and mTORC1 signaling, cell cycle and proliferation among promonocytes at response. Hematopoietic stem-progenitor cells had lower MCL1 expression levels at the time of response. Longitudinal cytometry by time of flight (CyTOF) in BM MNCs is underway to confirm these findings at the protein level.

Conclusion: The combination of CDA, LDAC and VEN demonstrated encouraging clinical activity in both ND and R/R high-risk CMML, with no early mortality and manageable toxicity. Responses were accompanied by reductions in molecular disease burden and in ImMonos implicated in CMML persistence and transformation.

 

Guillermo Montalban-Bravo, MD: Solu Therapeutics - Research Funding; Rigel Pharmaceuticals - Research Funding; Takeda Oncology - Research Funding